Pacira BioSciences, Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
PCRX$36.46+0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(In thousands, except per share amounts)
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Revenues: | ||||
| Net product sales | $178,040 | $167,722 | $525,981 | $509,933 |
| Royalty revenue | 1,476 | 851 | 3,557 | 3,780 |
| Total revenues | 179,516 | 168,573 | 529,538 | 513,713 |
| Operating expenses: | ||||
| Cost of goods sold | 34,278 | 38,864 | 109,450 | 130,542 |
| Research and development | 25,966 | 19,104 | 79,859 | 57,680 |
| Selling, general and administrative | 91,797 | 74,333 | 267,151 | 214,485 |
| Amortization of acquired intangible assets | 14,322 | 14,322 | 42,966 | 42,966 |
| Goodwill impairment | — | 163,243 | — | 163,243 |
| Contingent consideration charges (gains), acquisition-related expenses, restructuring and other | 6,791 | (1,766) | 13,261 | 2,872 |
| Total operating expenses | 173,154 | 308,100 | 512,687 | 611,788 |
| Income (loss) from operations | 6,362 | (139,527) | 16,851 | (98,075) |
| Other income (expense): | ||||
| Interest income | 8,534 | 5,482 | 20,437 | 14,134 |
| Interest expense | (4,279) | (4,689) | (13,554) | (11,889) |
| (Loss) gain on early extinguishment of debt | (983) | — | (983) | 7,518 |
| Other, net | (110) | (122) | (6,448) | (320) |
| Total other income (expense), net | 3,162 | 671 | (548) | 9,443 |
| Income (loss) before income taxes | 9,524 | (138,856) | 16,303 | (88,632) |
| Income tax expense | (4,092) | (4,610) | (10,906) | (26,969) |
| Net income (loss) | $5,432 | $(143,466) | $5,397 | $(115,601) |
| Net income (loss) per common share: | ||||
| Basic and diluted net income (loss) per common share | $0.12 | $(3.11) | $0.12 | $(2.50) |
| Weighted average common shares outstanding: | ||||
| Basic | 44,038 | 46,134 | 45,257 | 46,269 |
| Diluted | 44,459 | 46,134 | 45,729 | 46,269 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.